Paul L. Boutz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul L. Boutz has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Xueyang He
University of Rochester Medical Center, Department of Biochemistry and Biophysics, Center for RNA Biology, Rochester, NY, USA
4 shared publications- Clara L. Kielkopf
Center for RNA Biology and Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
3 shared publications - Mary J. Pulvino
University of Rochester School of Medicine and Dentistry
3 shared publications - Sarah Loerch
University of California, Santa Cruz, Department of Chemistry and Biochemistry, Santa Cruz, CA
3 shared publications - Craig J. Thomas
National Institutes of Health
2 shared publications - Dakarai E. Esgdaille
Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, USA
2 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Springer Nature in Cell Death Discovery
Long non-coding RNA NEAT1 drives nuclear condensates regulating gene expression and ferroptosis vulnerability in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor patient outcomes due to development of tumor cell drug resistance impacting treatment efficacy. Shifts in tumor cell transcriptional subtypes from well-differentiated classical to poorly differentiated basal-like cells can drive PDAC chemotherapeutic resistance. Such transcriptomic changes have been linked to cellular metabolic states, but how coordination of transcriptional and metabolic programs is mediated at the molecular level remains unclear. The stress-responsive long noncoding RNA NEAT1 , an essential constituent of nuclear condensates called paraspeckles, has been associated with classical PDAC and was previously linked to regulation of cellular metabolism. In this study, we utilized a high-throughput drug screening approach in NEAT1 -deficient cancer cells to uncover functional metabolic targets in these cells, identifying ferroptosis via GPX4 inhibition as a major vulnerability of cells lacking paraspeckles. We find that the paraspeckle-forming isoform of NEAT1 is central to ferroptosis suppression, and we extend these results into PDAC cell line models with genetic suppression or activation of NEAT1 . We find that NEAT1 -nucleated paraspeckles underlie the expression program tied to the classical PDAC subtype and promote ferroptosis resistance. We pinpoint the paraspeckle-suppressive RNA-binding protein QKI, associated with basal-like PDAC, as a positive regulator of ferroptosis susceptibility, possibly through its suppression of paraspeckles. These results link NEAT1 and regulation of paraspeckle condensates to subtype-specific ferroptosis susceptibility in PDAC and offer novel avenues for targeting metabolic vulnerabilities of pancreatic cancer cells on the basis of transcriptional subtype.
- 17 October 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessLong non-coding RNA NEAT1 drives nuclear condensates regulating gene expression and ferroptosis vulnerability in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor patient outcomes due to development of tumor cell drug resistance impacting treatment efficacy. Shifts in tumor cell transcriptional subtypes from well-differentiated classical to poorly differentiated basal-like cells can drive PDAC chemotherapeutic resistance. Such transcriptomic changes have been linked to cellular metabolic states, but how coordination of transcriptional and metabolic programs is mediated at the molecular level remains unclear. The stress-responsive long noncoding RNA NEAT1 , an essential constituent of nuclear condensates called paraspeckles, has been associated with classical PDAC and was previously linked to regulation of cellular metabolism. In this study, we utilized a high-throughput drug screening approach in NEAT1 -deficient cancer cells to uncover functional metabolic targets in these cells, identifying ferroptosis via GPX4 inhibition as a major vulnerability of cells lacking paraspeckles. We find that the paraspeckle-forming isoform of NEAT1 is central to ferroptosis suppression, and we extend these results into PDAC cell line models with genetic suppression or activation of NEAT1 . We find that NEAT1 -nucleated paraspeckles underlie the expression program tied to the classical PDAC subtype and promote ferroptosis resistance. We pinpoint the paraspeckle-suppressive RNA-binding protein QKI, associated with basal-like PDAC, as a positive regulator of ferroptosis susceptibility, possibly through its suppression of paraspeckles. These results link NEAT1 and regulation of paraspeckle condensates to subtype-specific ferroptosis susceptibility in PDAC and offer novel avenues for targeting metabolic vulnerabilities of pancreatic cancer cells on the basis of transcriptional subtype.
- Open Access
CDK12 and CDK13 suppress distinct intronic polyadenylation sites
Cyclin-dependent kinases CDK12 and CDK13 are RNA polymerase II C-terminal domain Ser2 kinases that regulate transcriptional elongation and co-transcriptional RNA processing. Loss-of-function (LOF) mutations in these kinases are observed in multiple cancers and are characterized by increased intronic polyadenylation (IPA), which generates prematurely terminated transcripts and can give rise to novel intronic peptides. To investigate the distinct contributions of CDK12 and CDK13 to suppressing early transcriptional termination, we modeled selective kinase inhibition in OVCAR4 ovarian cancer cells using THZ531, a dual CDK12/13 inhibitor. A CRISPR-engineered CDK12 C1039S mutation conferred THZ531 resistance, enabling functional distinction between CDK12 and CDK13 LOF conditions. Using Poly(A) Click-seq (PACseq) across a six-point inhibitor dose curve, we identified thousands of IPA sites with distinct dose-response behaviors, allowing us to classify CDK12- and CDK13-dependent subsets. Oxford Nanopore long-read sequencing confirmed premature termination events and revealed full-length isoform switches, demonstrating how IPA alters coding potential by truncating protein domains and producing novel, intronically encoded peptide sequences. In parallel, integration of long-read transcriptomes with mass spectrometry data identified peptides derived from IPA isoforms, confirming that intronic sequences can be translated. Together, these findings establish distinct roles for CDK12 and CDK13 in maintaining transcript integrity, demonstrate that IPA transcripts are not only abundant but also translationally competent, and provide evidence for a mechanistic link between transcriptional dysregulation and the generation of novel peptide isoforms in CDK12/13-deficient cancers. These results highlight a potential therapeutic vulnerability through the exploitation of IPA-derived peptides as tumor-specific neoantigens.
Open AccessCDK12 and CDK13 suppress distinct intronic polyadenylation sites
Cyclin-dependent kinases CDK12 and CDK13 are RNA polymerase II C-terminal domain Ser2 kinases that regulate transcriptional elongation and co-transcriptional RNA processing. Loss-of-function (LOF) mutations in these kinases are observed in multiple cancers and are characterized by increased intronic polyadenylation (IPA), which generates prematurely terminated transcripts and can give rise to novel intronic peptides. To investigate the distinct contributions of CDK12 and CDK13 to suppressing early transcriptional termination, we modeled selective kinase inhibition in OVCAR4 ovarian cancer cells using THZ531, a dual CDK12/13 inhibitor. A CRISPR-engineered CDK12 C1039S mutation conferred THZ531 resistance, enabling functional distinction between CDK12 and CDK13 LOF conditions. Using Poly(A) Click-seq (PACseq) across a six-point inhibitor dose curve, we identified thousands of IPA sites with distinct dose-response behaviors, allowing us to classify CDK12- and CDK13-dependent subsets. Oxford Nanopore long-read sequencing confirmed premature termination events and revealed full-length isoform switches, demonstrating how IPA alters coding potential by truncating protein domains and producing novel, intronically encoded peptide sequences. In parallel, integration of long-read transcriptomes with mass spectrometry data identified peptides derived from IPA isoforms, confirming that intronic sequences can be translated. Together, these findings establish distinct roles for CDK12 and CDK13 in maintaining transcript integrity, demonstrate that IPA transcripts are not only abundant but also translationally competent, and provide evidence for a mechanistic link between transcriptional dysregulation and the generation of novel peptide isoforms in CDK12/13-deficient cancers. These results highlight a potential therapeutic vulnerability through the exploitation of IPA-derived peptides as tumor-specific neoantigens.
- Open Access
Phosphorylation-mediated regulation of the essential splicing factor PUF60
PUF60 is a splicing factor related to the polypyrimidine-tract binding protein U2AF2. PUF60 is deleted in developmental disorders such as Verheij syndrome and amplified in approximately 8% of cancers. Thus, both increases and decreases in PUF60 expression can have profound physiological effects. However, little is known about how changes in PUF60 expression impact global splicing patterns. Here, we created a model system of CRISPRa/i in mouse stem cells (mESCs) to transcriptionally upregulate or downregulate Puf60. Our results uncovered extensive transcriptional, post-transcriptional, and post-translational regulation of Puf60 protein expression. We observed that Puf60 protein levels in normal mESCs drop dramatically at a critical cell density, leading to cell death. Puf60 is very essential in stem cells, and its repression causes cell death and impacts specific splicing events, including its own splicing autoregulation, providing valuable insights into the functional consequences of PUF60 dysregulation. Analysis of phosphoprotein data revealed phosphorylation of threonine at the N-terminus of PUF60. Our results showed that mutating threonine to glutamate downregulates the protein and alters its localization. Thus, our study reveals a novel regulatory mechanism of Puf60 phosphorylation that mediates its function and may be related to its frequent overexpression in cancer cells.
Open AccessPhosphorylation-mediated regulation of the essential splicing factor PUF60
PUF60 is a splicing factor related to the polypyrimidine-tract binding protein U2AF2. PUF60 is deleted in developmental disorders such as Verheij syndrome and amplified in approximately 8% of cancers. Thus, both increases and decreases in PUF60 expression can have profound physiological effects. However, little is known about how changes in PUF60 expression impact global splicing patterns. Here, we created a model system of CRISPRa/i in mouse stem cells (mESCs) to transcriptionally upregulate or downregulate Puf60. Our results uncovered extensive transcriptional, post-transcriptional, and post-translational regulation of Puf60 protein expression. We observed that Puf60 protein levels in normal mESCs drop dramatically at a critical cell density, leading to cell death. Puf60 is very essential in stem cells, and its repression causes cell death and impacts specific splicing events, including its own splicing autoregulation, providing valuable insights into the functional consequences of PUF60 dysregulation. Analysis of phosphoprotein data revealed phosphorylation of threonine at the N-terminus of PUF60. Our results showed that mutating threonine to glutamate downregulates the protein and alters its localization. Thus, our study reveals a novel regulatory mechanism of Puf60 phosphorylation that mediates its function and may be related to its frequent overexpression in cancer cells.
- Open Access
SF3B1 Phosphorylation Prompts U2AF2 Dissociation for Widespread Control of pre-mRNA Splicing
Reversible pre-mRNA splicing factor phosphorylation is a well-documented feature of spliceosome assembly, activation, and disassembly, yet its functional and mechanistic roles are still emerging. SF3B1, a core spliceosome subunit, is extensively phosphorylated before the first catalytic step of pre-mRNA splicing. Intriguingly, most SF3B1 phosphorylation sites surround its binding sites for U2AF2, an early-stage pre-mRNA splicing factor. Here, we discovered that SF3B1 phosphorylation significantly decreases its association with U2AF2. We determined two crystal structures revealing electrostatic repulsion between an acidic U2AF2 α-helix and the negatively-charged phosphoryl group of SF3B1. Variants with amino acid substitutions that prevent or mimic SF3B1 phosphorylation perturbed thousands of splice sites, primarily those marked by uridine-rich splice site signals recognized by U2AF2. Collectively, our findings demonstrate a widespread but previously unrecognized role for SF3B1 phosphorylation as a gateway for U2AF2 dissociation so that pre-mRNA splicing can proceed.
Open AccessSF3B1 Phosphorylation Prompts U2AF2 Dissociation for Widespread Control of pre-mRNA Splicing
Reversible pre-mRNA splicing factor phosphorylation is a well-documented feature of spliceosome assembly, activation, and disassembly, yet its functional and mechanistic roles are still emerging. SF3B1, a core spliceosome subunit, is extensively phosphorylated before the first catalytic step of pre-mRNA splicing. Intriguingly, most SF3B1 phosphorylation sites surround its binding sites for U2AF2, an early-stage pre-mRNA splicing factor. Here, we discovered that SF3B1 phosphorylation significantly decreases its association with U2AF2. We determined two crystal structures revealing electrostatic repulsion between an acidic U2AF2 α-helix and the negatively-charged phosphoryl group of SF3B1. Variants with amino acid substitutions that prevent or mimic SF3B1 phosphorylation perturbed thousands of splice sites, primarily those marked by uridine-rich splice site signals recognized by U2AF2. Collectively, our findings demonstrate a widespread but previously unrecognized role for SF3B1 phosphorylation as a gateway for U2AF2 dissociation so that pre-mRNA splicing can proceed.
- Open Access
The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing
Summary: Protein arginine methyltransferase 5 (PRMT5) is a promising cancer target, yet it’s unclear which PRMT5 roles underlie this vulnerability. Here, we establish that PRMT5 inhibition induces a special class of unspliced introns, called detained introns (DIs). To interrogate the impact of DIs, we depleted CLNS1A, a PRMT5 cofactor that specifically enables Sm protein methylation. We found that many, but not all, cell lines are CLNS1A-dependent and established that loss of viability is linked to loss of Sm protein methylation and DI upregulation. Finally, we discovered that PRMT5-regulated DIs, and the impacted genes, are highly conserved across human, and also mouse, cell lines but display little interspecies conservation. Despite this, human and mouse DIs have convergent impacts on proliferation by affecting essential components of proliferation-regulating complexes. Together, these data argue that the PRMT5-splicing axis, including appropriate DI splicing, underlies cancer’s vulnerability to PRMT5 inhibitors.
Open AccessThe PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing
Summary: Protein arginine methyltransferase 5 (PRMT5) is a promising cancer target, yet it’s unclear which PRMT5 roles underlie this vulnerability. Here, we establish that PRMT5 inhibition induces a special class of unspliced introns, called detained introns (DIs). To interrogate the impact of DIs, we depleted CLNS1A, a PRMT5 cofactor that specifically enables Sm protein methylation. We found that many, but not all, cell lines are CLNS1A-dependent and established that loss of viability is linked to loss of Sm protein methylation and DI upregulation. Finally, we discovered that PRMT5-regulated DIs, and the impacted genes, are highly conserved across human, and also mouse, cell lines but display little interspecies conservation. Despite this, human and mouse DIs have convergent impacts on proliferation by affecting essential components of proliferation-regulating complexes. Together, these data argue that the PRMT5-splicing axis, including appropriate DI splicing, underlies cancer’s vulnerability to PRMT5 inhibitors.
- Open Access
- 1 January 2024
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 14 (1344) , e4985
Updated Pseudo-seq Protocol for Transcriptome-Wide Detection of Pseudouridines
Pseudouridine (Ψ), the most prevalent modified base in cellular RNAs, has been mapped to numerous sites not only in rRNAs, tRNAs, and snRNAs but also mRNAs. Although there have been multiple techniques to identify Ψs, due to the recent development of sequencing technologies some reagents are not compatible with the current sequencer. Here, we show the updated Pseudo-seq, a technique enabling the genome-wide identification of pseudouridylation sites with single-nucleotide precision. We provide a comprehensive description of Pseudo-seq, covering protocols for RNA isolation from human cells, library preparation, and detailed data analysis procedures. The methodology presented is easily adaptable to any cell or tissue type with high-quality mRNA isolation. It can be used for discovering novel pseudouridylation sites, thus constituting a crucial initial step toward understanding the regulation and function of this modification.
- 1 January 2024
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 14 (1344) , e4985
Open AccessUpdated Pseudo-seq Protocol for Transcriptome-Wide Detection of Pseudouridines
Pseudouridine (Ψ), the most prevalent modified base in cellular RNAs, has been mapped to numerous sites not only in rRNAs, tRNAs, and snRNAs but also mRNAs. Although there have been multiple techniques to identify Ψs, due to the recent development of sequencing technologies some reagents are not compatible with the current sequencer. Here, we show the updated Pseudo-seq, a technique enabling the genome-wide identification of pseudouridylation sites with single-nucleotide precision. We provide a comprehensive description of Pseudo-seq, covering protocols for RNA isolation from human cells, library preparation, and detailed data analysis procedures. The methodology presented is easily adaptable to any cell or tissue type with high-quality mRNA isolation. It can be used for discovering novel pseudouridylation sites, thus constituting a crucial initial step toward understanding the regulation and function of this modification.
- Open Access
- 1 August 2023
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 37 (15-16) , 675-677
Putting a finger on histidine methylation
Specialized enzymes add methyl groups to the nitrogens of the amino acid histidine, altering the chemical properties of its imidazole ring and, in turn, the function of the modified (poly)peptide. In this issue ofGenes & Development, Shimazu and colleagues (pp. 724–742) make the remarkable discovery that CARNMT1 acts as a dual-specificity histidine methyltransferase, modifying both the small-molecule dipeptide carnosine and a set of proteins, predominantly within RNA-binding C3H zinc finger (C3H ZF) motifs. As a result, CARNMT1 modulates the activity of its protein targets to affect RNA processing and metabolism, ultimately contributing an essential function during mammalian development.
- 1 August 2023
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 37 (15-16) , 675-677
Open AccessPutting a finger on histidine methylation
Specialized enzymes add methyl groups to the nitrogens of the amino acid histidine, altering the chemical properties of its imidazole ring and, in turn, the function of the modified (poly)peptide. In this issue ofGenes & Development, Shimazu and colleagues (pp. 724–742) make the remarkable discovery that CARNMT1 acts as a dual-specificity histidine methyltransferase, modifying both the small-molecule dipeptide carnosine and a set of proteins, predominantly within RNA-binding C3H zinc finger (C3H ZF) motifs. As a result, CARNMT1 modulates the activity of its protein targets to affect RNA processing and metabolism, ultimately contributing an essential function during mammalian development.
- 21 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6642) , eabn7625
Oncogenic CDK13 mutations impede nuclear RNA surveillance
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 ( CDK13 ) is mutated in melanoma, and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We found recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.
- 21 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6642) , eabn7625
Oncogenic CDK13 mutations impede nuclear RNA surveillance
RNA surveillance pathways detect and degrade defective transcripts to ensure RNA fidelity. We found that disrupted nuclear RNA surveillance is oncogenic. Cyclin-dependent kinase 13 ( CDK13 ) is mutated in melanoma, and patient-mutated CDK13 accelerates zebrafish melanoma. CDK13 mutation causes aberrant RNA stabilization. CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Forced aberrant RNA expression accelerates melanoma in zebrafish. We found recurrent mutations in genes encoding nuclear RNA surveillance components in many malignancies, establishing nuclear RNA surveillance as a tumor-suppressive pathway. Activating nuclear RNA surveillance is crucial to avoid accumulation of aberrant RNAs and their ensuing consequences in development and disease.
- 9 February 2023
- Published by Elsevier in Molecular Cell
- Vol. 83 (4) , 637-651.e9
Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes
- 9 February 2023
- Published by Elsevier in Molecular Cell
- Vol. 83 (4) , 637-651.e9
Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes
- Open Access
- 1 July 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (8) , 102224
A UHM–ULM interface with unusual structural features contributes to U2AF2 and SF3B1 association for pre-mRNA splicing
- 1 July 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (8) , 102224
Open AccessA UHM–ULM interface with unusual structural features contributes to U2AF2 and SF3B1 association for pre-mRNA splicing